2219P AGITG ASCEND: Randomised, double-blind phase II trial of certepetide (CERT) or placebo (PLA) with gemcitabine (Gem) + nab-paclitaxel (Nab) in patients with untreated metastatic pancreatic ductal adenocarcinoma (mPDAC): Updated results including planned pooled placebo analysis - Dean, A.; Harris, M.T.; Sjoquist, K.; Gebski, V.; Karapetis, C.S.; Lomma, C.; Burge, M.; Steer, C.; Tebbutt, N.; Lee, B.; Jackson, C.; Day, F.; et al. (Annals of Oncology, 2025)